Physician profile
Brian Daniel Murphy
NPI 1679168553
$10,729.76
in general payments reported to CMS, 2019-2025
28 companies · $2,643 in 2025
The $2,643 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $1,775 · 2023: $2,448 · 2024: $2,894 · 2025: $2,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,404 · Travel and Lodging: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,404.11 |
| Travel and Lodging | $580.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,322.70 | 2021-2025 | |
| Lundbeck LLC | $1,089.70 | 2021-2025 | Vyepti |
| Pfizer INC. | $976.11 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $966.99 | 2023-2025 | Ajovy, Austedo Xr |
| Ipsen Innovation | $875.95 | 2023 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $656.85 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $510.71 | 2021-2022 | |
| Lilly USA, LLC | $369.01 | 2023-2024 | Emgality, Reyvow |
| Axsome Therapeutics, INC. | $307.15 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $269.29 | 2021-2024 | Rexulti |
| Impel Pharmaceuticals LLC | $246.47 | 2024-2025 | Trudhesa |
| Tonix Medicines, INC. | $147.06 | 2025 | Zembrace Symtouch |
| Impel Pharmaceuticals INC. | $139.03 | 2023 | Trudhesa |
| Upsher-Smith Laboratories LLC | $137.26 | 2023 | |
| Supernus Pharmaceuticals, INC. | $114.55 | 2022-2023 | Qelbree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.84 | 2023-2024 | Aimovig |
| Merck Sharp & Dohme LLC | $83.72 | 2023 | Belsomra |
| Scilex Pharmaceuticals INC. | $77.42 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $68.87 | 2023 | Iovera |
| Alkermes, INC. | $56.54 | 2022 | |
| Neurocrine Biosciences, INC. | $48.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.28 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.77 | 2021-2022 | |
| Adlon Therapeutics L.P. | $22.22 | 2021 | |
| Amneal Pharmaceuticals LLC | $20.96 | 2025 | Brekiya |
| Neos Therapeutics, LP | $20.24 | 2022 | |
| Bausch Health US, LLC | $19.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.